Regulus Therapeutics Inc (RGLS)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | PHARMACEUTICALS |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Joseph P. Hagan |
| Employees: | 30 |
| Web site: | regulusrx.com |
|
4224 CAMPUS POINT COURT, SUITE 210, SAN DIEGO, CA, 92121
858-202-6300
| |
| Date | Ratio |
|---|---|
| 2018-10-04 | 1:12 |
| 2022-06-29 | 1:10 |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Regulus Therapeutics Inc. engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies.
Please log in first to see chart